Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 2,951 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 2,951 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45. Following the transaction, the insider owned 123,499 shares of the company’s stock, valued at approximately $28,275,096.05. The trade was a 2.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $54,881.40.

Natera Stock Performance

NTRA stock traded up $11.32 during midday trading on Tuesday, reaching $248.74. 1,550,717 shares of the company were exchanged, compared to its average volume of 965,766. The company has a market cap of $34.41 billion, a price-to-earnings ratio of -108.62 and a beta of 1.62. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $249.15. The stock’s 50-day simple moving average is $224.18 and its 200 day simple moving average is $184.78.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the company posted ($0.26) EPS. The company’s quarterly revenue was up 34.7% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of the stock. Siemens Fonds Invest GmbH boosted its stake in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares in the last quarter. Guided Capital Wealth Management LLC raised its holdings in Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after purchasing an additional 66 shares during the last quarter. BOKF NA boosted its position in Natera by 1.9% during the third quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after purchasing an additional 69 shares in the last quarter. Silvant Capital Management LLC grew its holdings in Natera by 0.5% in the third quarter. Silvant Capital Management LLC now owns 13,488 shares of the medical research company’s stock valued at $2,171,000 after purchasing an additional 70 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in Natera by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Barclays boosted their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. BTIG Research boosted their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Stephens increased their price objective on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Wells Fargo & Company lifted their target price on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Piper Sandler increased their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Fifteen investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $235.29.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.